# Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

> **NCT05171335** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **The Methodist Hospital Research Institute** · enrollment: 50 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lenvatinib
- **PROCEDURE:** Transcatheter Arterial Chemoembolization

## Key facts

- **NCT ID:** NCT05171335
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-06-20
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05171335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05171335, "Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05171335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*